Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Hormone Receptor-Positive Breast Cancer | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Hormonal Therapy for Hormone Receptor-Positive Breast Cancer

2:02:23
 
Share
 

Manage episode 424632050 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Featuring perspectives from Dr Harold J Burstein, Ms Kelly Fischer, Dr Komal Jhaveri and Ms Melissa Rikal, including the following topics:

  • Introduction (0:00)
  • The Utility of Genomic Assays in Treatment Decision-Making for HR-Positive, HER2-Negative Localized Breast Cancer (10:21)
  • The Role of CDK4/6 Inhibitors in Therapy for HR-Positive Breast Cancer (37:18)
  • Oral Selective Estrogen Receptor Degraders in the Management of HR-Positive Metastatic Breast Cancer (mBC) (1:04:27)
  • Alpelisib and Capivasertib in Treatment for HR-Positive mBC (1:28:40)

NCPD information and select publications

  continue reading

1381 episodes

Artwork
iconShare
 
Manage episode 424632050 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Featuring perspectives from Dr Harold J Burstein, Ms Kelly Fischer, Dr Komal Jhaveri and Ms Melissa Rikal, including the following topics:

  • Introduction (0:00)
  • The Utility of Genomic Assays in Treatment Decision-Making for HR-Positive, HER2-Negative Localized Breast Cancer (10:21)
  • The Role of CDK4/6 Inhibitors in Therapy for HR-Positive Breast Cancer (37:18)
  • Oral Selective Estrogen Receptor Degraders in the Management of HR-Positive Metastatic Breast Cancer (mBC) (1:04:27)
  • Alpelisib and Capivasertib in Treatment for HR-Positive mBC (1:28:40)

NCPD information and select publications

  continue reading

1381 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide